

Manabu Natsumeda

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8664429/publications.pdf>

Version: 2024-02-01

74
papers

2,498
citations

430874

18
h-index

214800

47
g-index

80
all docs

80
docs citations

80
times ranked

4041
citing authors

#	ARTICLE	IF	CITATIONS
1	Guidelines for the use and interpretation of assays for monitoring autophagy (4th) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50,742 1,430	9.1	50,742
2	Clinicopathological factors related to regrowth of vestibular schwannoma after incomplete resection. <i>Journal of Neurosurgery</i> , 2011, 114, 1224-1231.	1.6	56
3	Gene expression signature-based prognostic risk score in patients with glioblastoma. <i>Cancer Science</i> , 2013, 104, 1205-1210.	3.9	56
4	Pharmacologic Wnt Inhibition Reduces Proliferation, Survival, and Clonogenicity of Glioblastoma Cells. <i>Journal of Neuropathology and Experimental Neurology</i> , 2015, 74, 889-900.	1.7	54
5	Induction of autophagy in temozolomide treated malignant gliomas. <i>Neuropathology</i> , 2011, 31, 486-493.	1.2	53
6	Immunohistochemical profiles of <i>DH</i> 1, <i>MGMT</i> and <i>P</i> 53: Practical significance for prognostication of patients with diffuse gliomas. <i>Neuropathology</i> , 2015, 35, 324-335.	1.2	52
7	The dual mTOR kinase inhibitor TAK228 inhibits tumorigenicity and enhances radiosensitization in diffuse intrinsic pontine glioma. <i>Cancer Letters</i> , 2017, 400, 110-116.	7.2	52
8	Targeting cancer stem-like cells in glioblastoma and colorectal cancer through metabolic pathways. <i>International Journal of Cancer</i> , 2017, 140, 10-22.	5.1	51
9	Accumulation of 2-hydroxyglutarate in gliomas correlates with survival: a study by 3.0-tesla magnetic resonance spectroscopy. <i>Acta Neuropathologica Communications</i> , 2014, 2, 158.	5.2	48
10	Dramatic response of BRAF V600E-mutant epithelioid glioblastoma to combination therapy with BRAF and MEK inhibitor: establishment and xenograft of a cell line to predict clinical efficacy. <i>Acta Neuropathologica Communications</i> , 2019, 7, 119.	5.2	47
11	Targeting Notch Signaling and Autophagy Increases Cytotoxicity in Glioblastoma Neurospheres. <i>Brain Pathology</i> , 2016, 26, 713-723.	4.1	42
12	Factors affecting functional outcomes in long-term survivors of intracranial germinomas: a 20-year experience in a single institution. <i>Journal of Neurosurgery: Pediatrics</i> , 2013, 11, 454-463.	1.3	38
13	Intraventricular pleomorphic xanthoastrocytoma with anaplastic features. <i>Neuropathology</i> , 2010, 30, 443-448.	1.2	29
14	High Incidence of Deep Vein Thrombosis in the Perioperative Period of Neurosurgical Patients. <i>World Neurosurgery</i> , 2018, 112, e103-e112.	1.3	29
15	MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas and MGMT Silencing to Temozolomide Sensitivity in IDH-Mutant Gliomas. <i>Neurologia Medico-Chirurgica</i> , 2018, 58, 290-295.	2.2	29
16	Thyroid-stimulating hormone (thyrotropin)-secretion pituitary adenoma in an 8-year-old boy: case report. <i>Pituitary</i> , 2012, 15, 110-115.	2.9	24
17	So-called bifocal tumors with diabetes insipidus and negative tumor markers: are they all germinoma?. <i>Neuro-Oncology</i> , 2021, 23, 295-303.	1.2	24
18	Epstein-Barr virus-associated primary central nervous system cytotoxic T-cell lymphoma. <i>Neuropathology</i> , 2013, 33, 436-441.	1.2	22

#	ARTICLE	IF	CITATIONS
19	High Detection Rate of <i>MYD88</i> Mutations in Cerebrospinal Fluid From Patients With CNS Lymphomas. <i>JCO Precision Oncology</i> , 2019, 3, 1-13.	3.0	21
20	Podoplanin Expression and IDH-Wildtype Status Predict Venous Thromboembolism in Patients with High-Grade Gliomas in the Early Postoperative Period. <i>World Neurosurgery</i> , 2019, 128, e982-e988.	1.3	20
21	A Hyperactive RelA/p65-Hexokinase 2 Signaling Axis Drives Primary Central Nervous System Lymphoma. <i>Cancer Research</i> , 2020, 80, 5330-5343.	0.9	19
22	Effectiveness of Maximal Safe Resection for Glioblastoma Including Elderly and Low Karnofsky Performance Status Patients: Retrospective Review at a Single Institute. <i>Neurologia Medico-Chirurgica</i> , 2012, 52, 570-576.	2.2	18
23	Reliable diagnosis of IDH-mutant glioblastoma by 2-hydroxyglutarate detection: a study by 3-T magnetic resonance spectroscopy. <i>Neurosurgical Review</i> , 2018, 41, 641-647.	2.4	18
24	Comparison of circulating tumor DNA between body fluids in patients with primary central nervous system lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 3587-3589.	1.3	18
25	MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas. <i>Frontiers in Oncology</i> , 2019, 9, 1568.	2.8	18
26	HSP90 Inhibition Overcomes Resistance to Molecular Targeted Therapy in <i>BRAFV600E</i> -mutant High-grade Glioma. <i>Clinical Cancer Research</i> , 2022, 28, 2425-2439.	7.0	17
27	Near-infrared spectroscopic study and the Wada test for presurgical evaluation of expressive and receptive language functions in glioma patients: With a case report of dissociated language functions. <i>Neuroscience Letters</i> , 2012, 510, 104-109.	2.1	14
28	Suppressed Expression of Autophagosomal Protein <i>LC3</i> in Cortical Tubers of Tuberous Sclerosis Complex. <i>Brain Pathology</i> , 2013, 23, 254-262.	4.1	14
29	Neuronal differentiation associated with <i>Gli3</i> expression predicts favorable outcome for patients with medulloblastoma. <i>Neuropathology</i> , 2014, 34, 1-10.	1.2	12
30	Synchronized multiple regression of diagnostic radiation-induced rather than spontaneous: disseminated primary intracranial germinoma in a woman: a case report. <i>Journal of Medical Case Reports</i> , 2011, 5, 39.	0.8	11
31	Advantages of Dose-dense Methotrexate Protocol for Primary Central Nervous System Lymphoma: Comparison of Two Different Protocols at a Single Institution. <i>Neurologia Medico-Chirurgica</i> , 2013, 53, 797-804.	2.2	11
32	Therapeutic Targeting of EZH2 and BET BRD4 in Pediatric Rhabdoid Tumors. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 715-726.	4.1	11
33	Anaplastic astrocytoma with angiocentric ependymal differentiation. <i>Neuropathology</i> , 2011, 31, 292-298.	1.2	10
34	EGFRVIII Is Expressed in Cellular Areas of Tumor in a Subset of Glioblastoma. <i>Neurologia Medico-Chirurgica</i> , 2019, 59, 89-97.	2.2	10
35	Indication of intraoperative immunohistochemistry for accurate pathological diagnosis of brain tumors. <i>Brain Tumor Pathology</i> , 2011, 28, 239-246.	1.7	9
36	Chemical Screening Identifies EUrd as a Novel Inhibitor Against Temozolomide-Resistant Glioblastoma-Initiating Cells. <i>Stem Cells</i> , 2016, 34, 2016-2025.	3.2	9

#	ARTICLE	IF	CITATIONS
37	Predicting BRAF V600E mutation in glioblastoma: utility of radiographic features. <i>Brain Tumor Pathology</i> , 2021, 38, 228-233.	1.7	9
38	Late relapse of primary central nervous system lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 475-477.	1.3	8
39	Malignant Hyperthermia and Cerebral Venous Sinus Thrombosis After Ventriculoperitoneal Shunt in Infant with Schizencephaly and COL4A1 Mutation. <i>World Neurosurgery</i> , 2019, 127, 446-450.	1.3	8
40	Inhibition of enhancer of zest homologue 2 is a potential therapeutic target for high-grade MYC medulloblastoma. <i>Neuropathology</i> , 2019, 39, 71-77.	1.2	8
41	Low Detection Rate of H3K27M Mutations in Cerebrospinal Fluid Obtained from Lumbar Puncture in Newly Diagnosed Diffuse Midline Gliomas. <i>Diagnostics</i> , 2021, 11, 681.	2.6	8
42	Necessity for craniospinal irradiation of germinoma with positive cytology without spinal lesion on MR imaging: A controversy. <i>Neuro-Oncology Advances</i> , 2021, 3, v086.	0.7	7
43	Efficacy of BRAF inhibitor and anti-EGFR antibody in colorectal neuroendocrine carcinoma. <i>Clinical Journal of Gastroenterology</i> , 2022, 15, 413-418.	0.8	7
44	Identification and validation of a gene expression signature that predicts outcome in malignant glioma patients. <i>International Journal of Oncology</i> , 2012, 40, 721-30.	3.3	6
45	Efficacy and safety of nivolumab in Japanese patients with first recurrence of glioblastoma: an open-label, non-comparative study. <i>International Journal of Clinical Oncology</i> , 2021, 26, 2205-2215.	2.2	6
46	Long-term survivors of primary central nervous system lymphoma. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 101-107.	1.3	5
47	GLI3-Associated With Neuronal Differentiation in SHH-Activated and WNT-Activated Medulloblastoma. <i>Journal of Neuropathology and Experimental Neurology</i> , 2021, 80, 129-136.	1.7	5
48	The Real-World status and risk factors for a poor prognosis in elderly patients with primary central nervous system malignant lymphomas: a multicenter, retrospective cohort study of the Tohoku Brain Tumor Study Group. <i>International Journal of Clinical Oncology</i> , 2022, 27, 77-94.	2.2	5
49	Molecular Features and Prognostic Factors of Pleomorphic Xanthoastrocytoma: A Collaborative Investigation of the Tohoku Brain Tumor Study Group. <i>Neurologia Medico-Chirurgica</i> , 2020, 60, 543-552.	2.2	4
50	Detection of 2-Hydroxyglutarate by 3.0-Tesla Magnetic Resonance Spectroscopy in Gliomas with Rare IDH Mutations: Making Sense of "False-Positive" Cases. <i>Diagnostics</i> , 2021, 11, 2129.	2.6	4
51	Clinicopathological risk factors for a poor prognosis of primary central nervous system lymphoma in elderly patients in the Tohoku and Niigata area: a multicenter, retrospective, cohort study of the Tohoku Brain Tumor Study Group. <i>Brain Tumor Pathology</i> , 2022, 39, 139-150.	1.7	4
52	Less-invasive diagnosis of disseminated epithelioid glioblastoma harboring BRAF V600E mutation by cerebrospinal fluid analysis: A case report. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, e04551.	0.5	2
53	Novel Repositioning Therapy for Drug-Resistant Glioblastoma: In Vivo Validation Study of Clindamycin Treatment Targeting the mTOR Pathway and Combination Therapy with Temozolomide. <i>Cancers</i> , 2022, 14, 770.	3.7	2
54	Topoisomerase II α immunoreactivity (IR) co-localizes with neuronal marker-IR but not glial fibrillary acidic protein-IR in GLI3-positive medulloblastomas: an immunohistochemical analysis of 124 medulloblastomas from the Japan Children's Cancer Group. <i>Brain Tumor Pathology</i> , 2021, 38, 109-121.	1.7	1

#	ARTICLE	IF	CITATIONS
55	Four-dimensional multifusion imaging for assessment of meningioma hemodynamics. <i>Interdisciplinary Neurosurgery: Advanced Techniques and Case Management</i> , 2021, 24, 101118.	0.3	1
56	DS-02 * INDUCTION OF AUTOPHAGY MARKERS IN GLIOMAS FOLLOWING PHARMACOLOGICAL NOTCH BLOCKADE. <i>Neuro-Oncology</i> , 2014, 16, v65-v65.	1.2	0
57	Central nervous system lymphoma with the α target sign α on magnetic resonance imaging mimicking cerebral toxoplasmosis. <i>Neurology and Clinical Neuroscience</i> , 2014, 2, 21-22.	0.4	0
58	PTPS-22DUAL mTOR KINASE INHIBITOR (MLN0128) MARKEDLY INDUCES GROWTH SUPPRESSION AND APOPTOSIS IN DIFFUSE INTRINSIC PONTINE GLIOMA CELL LINES. <i>Neuro-Oncology</i> , 2015, 17, v184.1-v184.	1.2	0
59	MTR-10PHARMACOLOGICAL NOTCH BLOCKADE IN GLIOMAS INDUCES AUTOPHAGY AND COMBINATION TREATMENT WITH AN AUTOPHAGY INHIBITOR INCREASES TUMOR CELL DEATH. <i>Neuro-Oncology</i> , 2015, 17, v126.2-v126.	1.2	0
60	HG-69CELL CULTURE CONDITIONS AFFECT DIFFUSE INTRINSIC PONTINE GLIOMA EPIGENETICS AND RESPONSE TO THERAPEUTIC AGENTS. <i>Neuro-Oncology</i> , 2016, 18, iii64.1-iii64.	1.2	0
61	PATH-54. Gli3 INDUCES NEURONAL DIFFERENTIATION IN WNT- AND SHH- ACTIVATED MEDULLOBLASTOMA. <i>Neuro-Oncology</i> , 2017, 19, vi183-vi183.	1.2	0
62	PATH-46. NEURONAL DIFFERENTIATION IS INDUCED BY Gli3 IN WNT- AND SHH- ACTIVATED MEDULLOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi168-vi169.	1.2	0
63	PATH-50. HIGH DETECTION RATE OF MYD88MUTATIONS IN CEREBROSPINAL FLUID FROM PATIENTS WITH CENTRAL NERVOUS SYSTEM LYMPHOMAS. <i>Neuro-Oncology</i> , 2018, 20, vi169-vi169.	1.2	0
64	ML-11 DETECTION OF MYD88 MUTATIONS FROM CELL FREE DNA AIDS IN THE DIAGNOSIS OF CENTRAL NERVOUS SYSTEM LYMPHOMAS. <i>Neuro-Oncology Advances</i> , 2019, 1, ii34-ii34.	0.7	0
65	COT-21 EFFECT OF BEVACIZUMAB FOR PEDIATRIC HIGH GRADE GLIOMA. <i>Neuro-Oncology Advances</i> , 2019, 1, ii44-ii44.	0.7	0
66	Endovascular treatment of an infectious aneurysm using the selective provocative test and transcranial motor evoked potential monitoring under general anesthesia: a case report. <i>Acta Neurochirurgica</i> , 2021, , 1.	1.7	0
67	Choroid Plexus Papilloma in the Fourth Ventricle Associated with Pheochromocytoma: A Case Report. <i>NMC Case Report Journal</i> , 2021, 8, 727-731.	0.5	0
68	MBRS-06. Gli3 INDUCES NEURONAL DIFFERENTIATION IN WNT- AND SHH- ACTIVATED MEDULLOBLASTOMA. <i>Neuro-Oncology</i> , 2020, 22, iii399-iii400.	1.2	0
69	MBRS-32. TOPOISOMERASE II β INDUCES NEURONAL, BUT NOT GLIAL, DIFFERENTIATION IN MEDULLOBLASTOMA. <i>Neuro-Oncology</i> , 2020, 22, iii404-iii404.	1.2	0
70	ML-09 The REAL-WORLD of Elderly PCNSL Therapy in Tohoku and Niigata Area According to Retrospective Analysis: A Collaborative Investigation of the Tohoku Brain Tumor Study Group. <i>Neuro-Oncology Advances</i> , 2020, 2, ii17-ii17.	0.7	0
71	Visualization of cortical activation in human brain by flavoprotein fluorescence imaging. <i>Journal of Neurosurgery</i> , 2022, , 1-9.	1.6	0
72	GEN-7 Liquid biopsy in brain tumor patients -The present and future-. <i>Neuro-Oncology Advances</i> , 2021, 3, vi4-vi4.	0.7	0

#	ARTICLE	IF	CITATIONS
73	STMO-16 The usability of Detailed pre-operative 3D simulation image for Tumor Resection of High grade glioma. Neuro-Oncology Advances, 2021, 3, vi13-vi14.	0.7	0
74	ACT-05 Present and future of precision-based medicine using cancer genome panels. Neuro-Oncology Advances, 2020, 2, ii8-ii8.	0.7	0